The term cirrhosis-associated immune dysfunction (CAID) comprises the distinctive
spectrum of immune alterations associated with the course of end-stage liver disease …

Patients with compensated advanced chronic liver disease who develop clinically significant
portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left …

Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

This Practice Guidance from the American Association for the Study of Liver Disease
(AASLD) intends to coalesce best practice recommendations for the identification of portal …

Background & Aims Portal vein thrombosis (PVT) is a relatively frequent event in patients
with cirrhosis. While different risk factors for PVT have been reported, such as decreased …

Background and Aims Sustained virologic response (SVR) to interferon (IFN)‐free therapies
ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in …

The human hemostasis system is complex and poorly understood after decades of intense
scientific study. Despite multiple defects in routine coagulation laboratory studies in patients …

Background & Aims Baveno VII proposed liver stiffness measurement (LSM)/platelet count
(PLT)-based criteria ('ruled out,'LSM≤ 15 kPa plus PLT≥ 150 G/L;'ruled in': LSM≥ 25 kPa) …

OBJECTIVES: The objective of this study is to investigate predictive factors and long-term
outcomes ofde novoportal vein thrombosis (PVT) in cirrhosis. METHODS: The incidence and …

Background and Aims Recent evidence suggests that acute kidney injury (AKI) is the main
predictor of postparacentesis bleeding in patients with cirrhosis. To assess the factors …